Skip to content
Open in App
Biomarin Pharma logo

Biomarin Pharma

web2

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercia...

Symbol · 1BMRN
Company profile

About

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

People

Company team

EM

Elizabeth McKee Anderson

Independent Director

Company leadership profile.

MJ

Mark Joseph Enyedy

Independent Director

Company leadership profile.

IT

Ian T. Clark

Independent Chair of the Board

Company leadership profile.

AH

Alexander Hardy

President, CEO & Director

Company leadership profile.

RJ

Robert J. Hombach

Independent Director

Company leadership profile.

WH

Willard H. Dere

Independent Director

Company leadership profile.

MH

Maykin Ho

Independent Director

Company leadership profile.

BW

Barbara W. Bodem

Independent Director

Company leadership profile.

AM

Athena Maria Countouriotis

Independent Director

Company leadership profile.

TP

Timothy P. Walbert

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Biomarin Pharma.

Orbitrum research

Experts evaluating Biomarin Pharma

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment